{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:11:07Z","timestamp":1789719067842,"version":"4.0.1"},"reference-count":29,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2013,8,12]],"date-time":"2013-08-12T00:00:00Z","timestamp":1376265600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2013,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Clofarabine was the latest new drug to be approved, in 2004, for relapsed or refractory acute lymphoblastic leukaemia (<jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>). To investigate its value in the frontline treatment of <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content> we applied clofarabine 5\u00a0\u00d7\u00a040\u00a0mg\/m<jats:sup>2<\/jats:sup> in combination with pegylated asparaginase (<jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">ASP<\/jats:styled-content>) 1\u00a0\u00d7\u00a02500\u00a0iu\/m<jats:sup>2<\/jats:sup> in high risk <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content> patients as a novel post\u2010induction element in the German Co\u2010operative Study Group for treatment of <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content> (Co<jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>) trial 08\u201009. Newly diagnosed <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content> patients, defined by a significant minimal residual disease (<jats:styled-content style=\"fixed-case\">MRD<\/jats:styled-content>) load at the end of induction (B\u2010progenitor <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content> at day 29\u00a0\u2265\u00a010<jats:sup>\u22124<\/jats:sup> and T\u2010<jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content> at day 43\u00a0\u2265\u00a010<jats:sup>\u22123<\/jats:sup>) were eligible for this phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> trial. All other patients received the standard treatment consisting of high\u2010dose cytarabine (<jats:styled-content style=\"fixed-case\">HIDAC<\/jats:styled-content>) 4\u00a0\u00d7\u00a03\u00a0g\/m\u00b2 in combination with Peg\u2010<jats:styled-content style=\"fixed-case\">ASP<\/jats:styled-content> 2500\u00a0iu\/m\u00b2. Forty\u2010two patients (39 B\u2010progenitor; 3 T\u2010<jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>) fulfilled the criteria, were stratified and received the clofarabine\/<jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">ASP<\/jats:styled-content> treatment resulting in 24\/39 (61%) <jats:styled-content style=\"fixed-case\">MRD<\/jats:styled-content>\u2010negative B\u2010progenitor patients compared to 18\/39 (46%) after <jats:styled-content style=\"fixed-case\">HIDAC<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">ASP<\/jats:styled-content> in Co<jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content> 07\u201003. Overall, the toxicity profile of clofarabine\/<jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">ASP<\/jats:styled-content> was similar to <jats:styled-content style=\"fixed-case\">HIDAC<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">ASP<\/jats:styled-content> without unexpected severe side effects. Clofarabine combined with <jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">ASP<\/jats:styled-content> is safe and effective in the frontline treatment of <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>. A prospective, randomized trial is warranted to evaluate the antileukaemic efficacy of clofarabine versus <jats:styled-content style=\"fixed-case\">HIDAC<\/jats:styled-content> combined with <jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">ASP<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/bjh.12520","type":"journal-article","created":{"date-parts":[[2013,8,12]],"date-time":"2013-08-12T08:57:22Z","timestamp":1376297842000},"page":"240-247","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Clofarabine in combination with pegylated asparaginase in the frontline treatment of childhood acute lymphoblastic leukaemia: a feasibility report from the Co<scp>ALL<\/scp> 08\u201009 trial"],"prefix":"10.1111","volume":"163","author":[{"given":"Gabriele","family":"Escherich","sequence":"first","affiliation":[{"name":"Clinic of Paediatric Haematology and Oncology University Medical Centre Hamburg\u2010Eppendorf Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"zur Stadt","sequence":"additional","affiliation":[{"name":"Centre for Diagnostics University Medical Centre Hamburg\u2010Eppendorf Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Zimmermann","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology and Oncology Medical School Hannover Hannover Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin A.","family":"Horstmann","sequence":"additional","affiliation":[{"name":"Clinic of Paediatric Haematology and Oncology University Medical Centre Hamburg\u2010Eppendorf Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"CoALL study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,8,12]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00254573"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-010-1376-z"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2008.1.366"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24398"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)04058-6"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950100725"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.11.010"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.249"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.5"},{"key":"e_1_2_8_11_1","first-page":"6335","article-title":"Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukaemias","volume":"9","author":"Gandhi V.","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.262"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24112"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2122"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.8706"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0925"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07882.x"},{"key":"e_1_2_8_18_1","first-page":"2386","article-title":"Effects of 2\u2010chloro\u20109\u2010(2\u2010deoxy\u20102\u2010fluoro\u2010beta\u2010D\u2010arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5\u2032\u2010triphosphate","volume":"51","author":"Parker W.B.","year":"1991","journal-title":"Cancer Research"},{"key":"e_1_2_8_19_1","first-page":"111","article-title":"Use of clofarabine for acute childhood leukaemia","volume":"4","author":"Pession A.","year":"2010","journal-title":"Biologics"},{"key":"e_1_2_8_20_1","first-page":"371","article-title":"High\u2010dose cytarabine in acute leukaemia: toxicity and pharmacokinetics","volume":"67","author":"Pommier Y.","year":"1983","journal-title":"Cancer Treatment Reports"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.252"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-378943"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00684870"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1983.1.9.546"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.09.020"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402019"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/2162\u20103619\u20101\u201039"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404586"},{"key":"e_1_2_8_29_1","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood.V65.6.1407.bloodjournal6561407","article-title":"High\u2010dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukaemia in first remission: a pilot study","volume":"65","author":"Wolff S.N.","year":"1985","journal-title":"Blood"},{"key":"e_1_2_8_30_1","first-page":"3030","article-title":"Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2\u2010chloro\u20109\u2010(2\u2010deoxy\u20102\u2010fluoro\u2010beta\u2010D\u2010arabinofuranosyl) adenine","volume":"56","author":"Xie K.C.","year":"1996","journal-title":"Cancer Research"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.12520","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.12520","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T05:25:25Z","timestamp":1700630725000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.12520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,12]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.1111\/bjh.12520"],"URL":"https:\/\/doi.org\/10.1111\/bjh.12520","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,12]]},"assertion":[{"value":"2013-05-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-06-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-08-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}